OncoMatch/Clinical Trials/NCT07767630
Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma
Official title: An Exploratory Proof-of-Concept (POC) Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Fractionated Dosing of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma (Including a Run-in Phase)
Is NCT07767630 recruiting? Yes, currently enrolling (Oct 2026). This Early Phase 1 trial studies [211At]MABG for neuroblastoma (nb).
Treatment: [211At]MABG — Fractionated dosing of \[211At\]MABG Radiotherapy in Relapsed/Refractory Neuroblastoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Neuroblastoma
Biomarker criteria
Required: SLC6A2 mibg avidity
Patients diagnosed with MIBG avid lesions
Required: SLC6A2 mibg avidity
All measurable soft tissue lesions must be MIBG-avid
Demographics
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function and hematologic parameters
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07767630 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require SLC6A2?
Yes, SLC6A2 mibg avidity is a required biomarker for enrollment.
Does this trial require SLC6A2?
Yes, SLC6A2 mibg avidity is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 100 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages